Related Experiment Videos
Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation.
L Narhi1, S J Wood, S Steavenson
1Amgen, Inc., Thousand Oaks, California 91320-1789, USA.
The Journal of Biological Chemistry
|March 27, 1999
Summary
Parkinson's disease (PD) involves alpha-synuclein protein aggregation. Specific PD mutations accelerate this aggregation, suggesting it's a key step in disease development.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Parkinson's disease (PD) is a neurodegenerative disorder characterized by Lewy bodies, primarily composed of alpha-synuclein filaments.
- The pathogenic mechanism of alpha-synuclein mutations, the only known genetic causes of PD, remains unclear.
Purpose of the Study:
- To investigate the aggregation properties of wild-type and mutant alpha-synuclein in vitro.
- To determine the role of PD-linked mutations in alpha-synuclein aggregation.
Main Methods:
- Incubation of wild-type and mutant alpha-synuclein at physiological temperature.
- Monitoring the formation of insoluble fibrillar aggregates using in vitro methods.
Main Results:
- Both wild-type and mutant alpha-synuclein formed insoluble aggregates with antiparallel beta-sheet structure.
- PD-linked mutations (A30P and A53T) significantly accelerated aggregate formation compared to wild-type alpha-synuclein.
- Lag times for aggregate formation were 280h (wild-type), 180h (A30P), and 100h (A53T).
Conclusions:
- Alpha-synuclein aggregation is a critical step in Parkinson's disease pathogenesis.
- PD-associated mutations accelerate alpha-synuclein aggregation, providing insight into disease mechanisms.